SUMMARY Twenty patients with definite or classical rheumatoid arthritis entered and completed a sequential study of placebo for 1 week, oral indomethacin 25 mg 3 times a day for 3 weeks, and oral indomethacin 25 mg 3 times a day plus 100 mg indomethacin suppository at night for 3 weeks. Twelve of the patients had previously been classified as responders and eight as nonresponders to indomethacin by an independent assessor. At the end of each period patients were assessed by a blind observer for duration of morning stiffness, pain score, digital joint size, grip strength, articular index, analgesic tablet usage, and the patient's own overall global assessment and comparative global assessment. In 8 of the 9 tests used responders improved on indomethacin in comparison with placebo, while nonresponders did not improve. There were no significant differences between responders and nonresponders in the plasma half-life, plasma clearance of indomethacin, protein binding of indomethacin, or urinary excretion of free or conjugated indomethacin. There were no significant differences between responders and nonresponders in the urinary excretion of 7HDPA or in the platelet aggregation or platelet malonyldialdehyde production tests. In responders there was a significant positive correlation between the plasma indomethacin concentration (r=0 44, P<0 -05) and the percentage inhibition of malonyldialdehyde production by the platelets. However, in nonresponders this correlation, while significant (P<0 .05), was negative (r= -0 498). Both for responders and nonresponders there was a significant correlation between plasma indomethacin concentration and the percentage reduction in 7HDPA. There was no correlation between the clinical response and the plasma concentration of indomethacin. There appears to be a biochemical difference between responders and nonresponders, which, while not necessarily causally linked with the clinical response to indomethacin, is worthy of further study.
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Indomethacin (Indocid) has been used in the detecting those patients who will not respond to treatment of rheumatoid arthritis for over 10 years. therapy with indomethacin, and possible reasons Many patients get a worthwhile beneficial effect for failure to improve vary from a failure to take from it but a significant proportion of patients are the capsules to the presence of severe side effects. not improved (Broll et al., 1976; Co-operating This study was designed to compare a group of Indomethacin in rheumatoid arthritis 129
Methods

PATIENTS
A group of patients was selected for study who were judged by one of us (T.L.) to have either responded or not responded to a course of indomethacin over the previous 2 years. This information was noted but not revealed to the other investigators until the conclusion of the study. Twenty patients were selected, all of whom had classical or definite rheumatoid arthritis (Ropes et al., 1959) . Twelve patients were initially categorised as responders and 8 as nonresponders to indomethacin and their details are shown in Table 1 . Eight patients had previously had gold therapy and 4 had received corticosteroid therapy, though at least 5 years prior to the study.
TRIAL DESIGN
This was a single blind sequential study, the nature of which was explained to each patient and their informed consent obtained. Before the start of the study all anti-inflammatory drugs were stopped (indomethacin in 11 patients, ibuprofen in 5, and naproxen in 4). They were given matching indomethacin placebo capsules to be taken 3 times daily and a supply of paracetamol (16 patients) or Distalgesic (dextropropoxyphene and paracetamol) (4 patients). One week later they started active treatment with indomethacin 25 mg 3 times a day for a 3-week period. After this an indomethacin suppository (100 mg) was given each night in addition to 25 mg 3 times a day by mouth for a further 3-week period. One patient had aesthetic objections to the suppository and was given instead a 100 mg oral dose before sleep. For the final 3-week period 17 patients were then given probenecid 0 * 5 g twice daily in addition to indomethacin 25 mg 3 times a day by mouth as a means of increasing the plasma concentration of indomethacin. The results of the probenecid study are reported in detail elsewhere (Baber er al., 1978) . Three patients developed side effects during the suppository period and were given placebo probenecid tablets. (Boardman and Hart, 1967) giving the sum of all 10 values; (g) the articular index (Ritchie et al., 1968) ; and (h) the number of paracetamol or Distalgesic tablets consumed. At each visit the patient was weighed and questioned about the development of side effects, in particular headache and gastrointestinal irritation.
Blood samples were taken for the measurement of haemoglobin, white cell count, and erythrocyte sedimentation rate (ESR, Westergren). Blood samples were taken at 1100 h, 1200 h, 1400 h, and 1600 h. These blood samples were then centrifuged at 2000 rpm for 10 minutes, and the plasma was pipetted off and stored at -200C prior to analysis of the indomethacin concentration. Plasma indomethacin concentrations were measured by a recently developed sensitive and specific gas-liquid chromatographic method using electron capture detection . Plasma albumin and glubulin concentrations were measured by AutoAnalyzer. The protein binding of indomethacin was measured in each patient by the method of equilibrium dialysis using the Dianorm (Fisons, MSE Ltd.) (Weder and Bickel, 1970) . To patients' plasma (1 ml) containing indomethacin 300 ng/ml was added 0 2 [Ci of 14C indomethacin (Merck Sharpe and Dohme), and 0 5 ml of this plasma was then dialysed in duplicate against buffer. At least 1 plasma sample from each patient at each assessment was checked for the presence of salicylate by the method of Trinder (1954) . Blood (20 ml) was also taken at 1200 h into citrate, and this blood was used within 60 minutes for the assay of malonyldialdehyde production by the platelets as described by Keenan et al. (1977) .
A 24-hour urine collection was made on the day before each clinic visit. This urine was assayed for unchanged indomethacin content by the method of Sibeon et al. (1978) both before and after incubation with betaglucuronidase (Sigma Chemical Company) at pH 6 * 5. This enzyme converts indomethacin glucuronide back into unchanged indomethacin. The urinary output of 7a.-hydroxy-5, 1 1-diketotetranorprostane-1, 16 dioic acid (6HDPA) was also determined in 17 of the 20 patients. This metabolite is the main urinary metabolite of prostaglandins of the El and E2 series. 7 HDPA was measured by gas liquid chromatography linked to an LKB 9000 mass spectrometer using chemical ionisation (Walker et al., 1978) .
STATISTICAL METHODS
The area under the plasma indomethacin concentration versus time curve (AUC) over a dosage interval (8 hours) was measured by the trapezoidal method. On at least 1 occasion in each patient blood was taken prior to dosing with indomethacin at 0800 h (0 hour), and the plasma indomethacin concentration was not significantly different from that at 1600 h (8 hours after closing). In all other cases, then, the 8-hour concentration was also used as the concentration at zero time. The steady state plasma indomethacin concentration (Css) was calculated from the AUC:
Css=AUC/y where y is the dosage interval, in this case 8 hours.
The plasma half life of indomethacin was calculated by least squares regression analysis of the terminal exponential phase of the plasma indomethacin concentration profile. The plasma clearance of indomethacin was calculated from the formula: FD Plasma clearance =AUC (Alexanderson, 1972) , where F is the fraction of dose D absorbed. F is assumed to be one as shown by Alvan et al. (1975) .
The changes in each clinical assessment were correlated with the plasma indomethacin concentrations using linear regression analysis. The changes in subjective assessments with treatments were analysed by the sign test, and changes in objective assessments (grip strength, Ritchie articular index, and digital joint size) were analysed by the Wilcoxon sign sum rank test. Comparisons of the effects of different treatments on pharmacokinetic measurements and the analgesic tablet counts were made by Student's t test. Differences between chemical and biochemical analyses were also assessed by Student's t test.
Results
All 20 patients completed the trial. Twelve patients had been classed as responders and 8 as nonresponders to indomethacin prior to the study. The results are shown in Table 2 and the statistical analysis in Table 3. INDIVIDUAL CLINICAL ASSESSMENTS Ritchie articular index. The scoring fell in both treatment periods in comparison with placebo, but this was statistically significant only for responders on oral plus rectal treatment.
Pain score. Oral therapy and oral plus rectal therapy reduced the pain scores for responders in both oral and oral plus suppository periods. There were no significant differences in nonresponders.
Digitaljoint sizes. No significant changes were seen.
Duration of morning stiffness. Treatment reduced the duration of morning stiffness, and this reached statistical significance for responders on the combination of treatments.
Grip strength. Responders improved their grip strength significantly on both treatments in comparison with placebo, while there was no significant change in nonresponders.
Consumption of analgesic tablets. There was a significant reduction in the number of analgesic tablets consumed by responders in both oral and oral plus suppository periods (P < 0 * 05 and P <0*01 respectively). There was no significant reduction in the number of analgesic tablets consumed by nonresponders. The difference between responders and nonresponders in the placebo period (59-3±16-9 and 36-1±16'0) is not sig- group.bmj.com on June 21, 2017 -Published by http://ard.bmj.com/ Downloaded from placebo. There were no significant changes in weight, haemoglobin, white cell count, or ESR during the study.
Side effects. The percentage of patients reporting side effects is given in Table 4 . There were more general complaints (which often included headache and gastrointestinal disorders) on treatment than placebo. A history of headaches was elicited more frequently in both responders and nonresponders on combined treatment than with oral indomethacin, though the percentage was higher for responders. Gastrointestinal symptoms were more frequent on placebo for both groups.
PLASMA INDOMETHACIN CONCENTRATIONS
The steady state plasma indomethacin concentration as calculated from the area under the curve (AUC) correlated well with the 4-hour plasma concentration (the mid dosage interval) (r=0-931, n=60, P<0 001).
The pharmacokinetic data are shown in Table 5 . The mean plasma half of indomethacin was between 3 5 and 44I hours. There was no significant difference in plasma half life or AUC or plasma clearance of indomethacin between responders and nonresponders (P>0 1). The nonresponders to indomethacin failed to respond to the drug even though their plasma concentrations were not significantly different from those seen in the responders. In practice the concentration in nonresponders was slightly higher than that in responders. As expected, the AUC increased significantly (P <0 01) when the dose of indomethacin was increased by the addition of the suppository, but there were no significant changes in plasma half life of plasma clearance with the larger dose.
PROTEIN BINDING
The mean plasma albumin concentration in responders was 4 00±0 29 g/100 ml (40±2-9 g/l) (mean±SD) and in responders 4-2±0 24 g/lOOml (42±2-4 g/l), while the mean plasma globulin concentration was 3 50±0 57 g/100 ml (35±5 7 g/l) in responders and 3-37±0 32 g/100 ml (33 7±3 2 g/l) in nonresponders. These figures are not significantly different. There were no significant differences in protein binding of indomethacin between responders and nonresponders.
PLATELET STUDIES
The results of these studies are shown in Figs 1 and 2. Indomethacin produced a significant inhibition of platelet aggregation in all patients, and there were no significant differences between responders and nonresponders. Increasing the dose of indomethacin by the addition of the suppository did not cause a further significant inhibition of platelet aggregation (Fig. 1) . Indomethacin also caused a significant inhibition of the platelet production of malonyldialdehyde (see Fig. 2 ), though there were again no significant differences between responders and nonresponders. The increased dose of indomethacin did not result in any further significant inhibition of malonyldialdehyde production. 1  1264  7020  6144  538  9030   2780  2  2566  12687  8133  748  7920  2402  3  1205  5000  2035  243  7511  2608  4  2354  13390  3414  2140  6104  4608  5  2081  9520  4253  1631  9520   4316  6  895  6750  2597  870  6700  1147  7  754  5000  799  2338  9450  2622  8  1225  12530  4230  1704  16146  9546  9  238  638  1786  10  957  7250  584   11   1409  6936  6156  12  1613  12100 P <0 05; Fig. 4) . If the data from the probenecid period are included, the correlation coefficient improves to -r=0 504, (P<0 01, n=24). There was a significant positive correlation between the plasma concentration of indomethacin and the percentage inhibition of 7HDPA excretion Responders 7 of the 8 nonresponders. In both responders and nonresponders indomethacin significantly inhibited the urinary excretion of 7HDPA, but there were no significant differences between responders and nonresponders. Increasing the dose of indomethacin caused a further slight increase in the inhibition of 7HDPA excretion, but this was not statistically significant.
CORRELATIONS WITH PLASMA INDOMETHACIN CONCENTRATIONS
Clinical effects. There were no significant correlations between the plasma concentrations of indomethacin and the degree of improvement in the various clinical tests.
Side effects. The mean steady-state plasma concentrations in the patients experiencing headache on indomethacin after oral plus suppository treatments was higher for both responders (448 ng/ml) and nonresponders (457 ng/ml) compared with the corresponding means for all patients in each subgroup (307 ng/ml responders, 317 ng/ml nonresponders, P <0.01). No relation was seen between gastrointestinal side effects and blood levels.
Biochemical effects. For the group of patients as a whole there was no significant correlation between either the inhibition of platelet aggregation or the inhibition of malonyldialdehyde production and the plasma indomethacin concentration. However, among the 12 responders there was a significant positive correlation between the percentage inhibition of malonyldialdehyde production and the plasma concentration of indomethacin (r=0'441, n=24, P<0 05; see Fig. 3 ). If the data from the probenecid period are included the correlation becomes closer, with r=0 475, (P<0 01, n=36) . Among the 8 nonresponders there was also a significant correlation between the percentage inhibition of malonyldialdehyde production and the plasma concentration of indomethacin, only here the correlation was negative (r-=0-498, n=16, For suggest a difference between responders and nonnonresponders (7 patients) r=0*640, n= 14, P<0-01, responders. There is a positive correlation in both Y=254±0-08X.
responders and nonresponders between the plasma indomethacin concentration and the urinary excretion of 7HDPA. This would suggest that inin both responders and nonresponders (Fig. 5) . domethacin affects the synthesis of prostaglandin, For responders the correlation coefficient was El and E2 similarly in responders and nonresponders. r=0-437, n=20, P<005, and for nonresponders However, while there is a similar positive corr=0 640, n=14, P<0 01. The lines of identity are relation between the plasma indomethacin convery similar in both groups (Fig. 5) . For responders centration and the percentage inhibition of platelet there was a significant correlation between the malonyldialdehyde production in responders, there percentage change in 7HDPA excretion and the is a significant negative correlation between these percentage change in platelet malonyldialdehyde two variables in nonresponders. Thus, in nonproduction (r =0 602, n =20, P <0 01), but there was responders, as the plasma indomethacin conno such correlation for nonresponders (r =0.078).
centration increases there is less inhibition of malonyldialdehyde production. Malonyldialdehyde Discussion is only one of the products of prostaglandin synthetase activity in the platelets, the other products This study has confirmed the initial observation of a being prostaglandin E, thromboxane A2 and failure to respond to indomethacin in the 8 non-prostaglandin F2A. It is possible, therefore, that in responsive patients. No clear reason emerges to nonresponders indomethacin may have differing explain the reason for the failure to respond. The 2 effects on the various prostaglandin synthetase groups of patients were reasonably well matched enzymes compared to responders. More detailed with regard to sex and duration and severity of studies are in progress using 14C arachidonic acid in disease, though the responders had a slightly higher platelet studies to investigate this possibility. This incidence of positive latex fixation tests than non-finding of a potential biochemical difference between responders. The plasma indomethacin concentrations responders and nonresponders does not mean that were similar in both groups, indicating that initial the 2 findings are necessarily causally related. Furfailure to respond was unlikely to be due to a ther studies are needed to confirm these observations failure to take the drug. There were no significant and to see if the platelet malonyldialdehyde activity differences in the pharmacokinetics of indomethacin is linked with a clinical response to indomethacin. or in the protein binding of indomethacin between In this study, when individual nonresponding responders and nonresponders. The failure to patients were examined, their platelet malonylrespond to indomethacin did not seem to be a dialdehyde response to indomethacin was of no question of the dose used, since the nonresponders value in predicting their individual clinical response showed no sign of improving even when the dose to indomethacin.
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